Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE

by Zacks Equity Research

Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.

Zacks Equity Research

Globus Medical (GMED) Hurt by Dull Global Growth, Low Margins

by Zacks Equity Research

Pricing continues to remain a major headwind for Globus Medical (GMED).

Zacks Equity Research

Why Is Globus Medical (GMED) Down 5.3% Since Last Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q4.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 13.73% and -0.34%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) US Spine Grows, Pricing Pressure Stays

by Zacks Equity Research

Globus Medical's (GMED) recent product launches are seeing tremendous uptake.

Zacks Equity Research

Globus Medical (GMED) Gains From Robot Sales Amid Pandemic Blues

by Zacks Equity Research

Globus Medical (GMED) saw a visible rebound in its revenue trend in the third quarter.

Zacks Equity Research

Here's Why You Should Hold on to Globus Medical (GMED) for Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement in the third quarter.

Zacks Equity Research

Globus Medical (GMED) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) is optimistic about maintaining robust product portfolio along with strength in its domestic spine business.

Zacks Equity Research

Why Is Globus Medical (GMED) Up 20.5% Since Last Earnings Report?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings Beat, U.S. Business Strong

by Zacks Equity Research

Globus Medical's (GMED) spinal implant business performance varies by region in Q3.

Zacks Equity Research

Globus Medical (GMED) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 58.06% and 9.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

by Zacks Equity Research

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

Zacks Equity Research

Medtronic Announces U.S. Launch of Adaptix, Expands Portfolio

by Zacks Equity Research

Medtronic (MDT) introduces fully-navigated titanium implant procedure in the United States with the launch of Adaptix Interbody System.

Zacks Equity Research

Walgreens' Pharmacy International Arm Faces Coronavirus Woes

by Zacks Equity Research

Walgreens (WBA) expects the adverse impact of COVID-19 to continue in the fiscal fourth quarter.

Zacks Equity Research

Integra (IART) Preliminary Q3 Results Show Recovery in Sales

by Zacks Equity Research

Integra's (IART) sales improvement in the third quarter is broad-based across the major franchises as per preliminary statement.

Zacks Equity Research

Here's Why You Should Add NEOGEN (NEOG) to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

Zacks Equity Research

FDA Amends Hologic's Aptima's EUA for Asymptomatic Testing

by Zacks Equity Research

The FDA's modified EUA for Hologic's (HOLX) Aptima SARS-CoV-2 assay includes testing of asymptomatic individuals and symptomatic pooling protocol to curb the spread of coronavirus.

Zacks Equity Research

Here's Why You Should Add Globus Medical to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Urmimala Biswas headshot

LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA

by Urmimala Biswas

According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.

Zacks Equity Research

Align Technology Rides on Invisalign Amid Coronavirus Woes

by Zacks Equity Research

Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.

Zacks Equity Research

Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications

by Zacks Equity Research

Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.

Zacks Equity Research

LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes

by Zacks Equity Research

There has been a steady recovery in the Base Business of LabCorp (LH).